N-(1-Adamantyl)-2-oxo-4-phenylpyrrolidine-1-acetamide | 77472-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-(1-Adamantyl)-2-oxo-4-phenylpyrrolidine-1-acetamide
• 英文别名: N-(1-adamantyl)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide
• CAS: 77472-73-2
• 化学式: C₂₂H₂₈N₂O₂
• 分子量: 352.477
• InChiKey: XDQJJNMHGMKEDR-UHFFFAOYSA-N

物化性质

• 熔点：
  108-109 °C(Solv: heptane (142-82-5))
• 沸点：
  598.4±49.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-氧代-4-苯基-1-吡咯烷乙酸乙酯 在 氢氧化钾 、 三乙胺 、 氯甲酸异丁酯 作用下， 以 乙醇 为溶剂， 反应 7.5h， 生成 N-(1-Adamantyl)-2-oxo-4-phenylpyrrolidine-1-acetamide
  参考文献：
  名称：

  4-苯基吡咯烷酮-2-乙酰胺的合成及解痉活性

  摘要：

  众所周知 [i] 各种化合物的解痉特性经常与结构元素的存在有关，这些结构元素包括一个苯基或一个苯环，这些元素相对于一个酰胺基团特别取向，通常是一个片段杂环系统（巴比妥酸、乙内酰脲、吡唑烷二酮、琥珀酰亚胺等）。pyrrolidone-2 的苯基衍生物满足这些要求，事实上，在 5-phenylpyrrolidone-2 的衍生物中发现了具有解痉活性的化合物 [2]。因此，4-苯基吡咯烷酮-2 的衍生物可能显示出明确的解痉作用，正如所指出的，它是苯基替代物 2-吡咯烷酮中在一些其他药理学特性中最活跃的 [3]。

  DOI：

  10.1007/bf00765621

文献信息

• Pharmaceutical use of substituted amides
  申请人：Andersen Sune Henrik

  公开号：US20060111366A1

  公开（公告）日：2006-05-25

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文介绍了使用取代酰胺来调节11β-羟化甾体脱氢酶1型（11βHSD1）的活性以及将这些化合物用作制药组合物的方法。还介绍了一类新型的取代酰胺，它们在治疗中的应用、包含这些化合物的制药组合物以及它们在药物制剂制造中的应用。这些化合物是11βHSD1的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低活性糖皮质激素细胞内浓度的医学疾病。
• Amide Derivatives and Pharmaceutical Use Thereof
  申请人：Andersen Henrik Sune

  公开号：US20090264414A1

  公开（公告）日：2009-10-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟化类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为药物组分的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括含有这些化合物的药物组分以及它们在制造药物中的用途。这些化合物是调节剂，更具体地说是11βHSD1活性的抑制剂，可用于治疗、预防和/或预防一系列医学疾病，其中降低细胞内活性糖皮质激素的浓度是可取的。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。
• Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
  申请人：NOVO NORDISK A/S

  公开号：EP1862181A2

  公开（公告）日：2007-12-05

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和降压药组成的联合疗法，可用于治疗、预防和降低胰岛素抵抗、血脂异常、肥胖、高血压及其他相关疾病和紊乱的发病风险。
• Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
  申请人：Kampen Tejlgaard Gita Camilla

  公开号：US20060094699A1

  公开（公告）日：2006-05-04

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。